Protagonist Therapeutics Inc (PTGX.OQ)
8.71USD
20 Apr 2018
$-0.04 (-0.46%)
$8.75
$8.72
$8.79
$8.55
7,184
59,358
$23.68
$7.85
Latest Key Developments (Source: Significant Developments)
Protagonist Therapeutics Discontinues Phase 2B Propel Trial Of PTG-100
March 26 (Reuters) - Protagonist Therapeutics Inc
Protagonist Therapeutics initiates phase 1 trial of oral peptide PTG-200
Nov 9 (Reuters) - Protagonist Therapeutics Inc
Protagonist Therapeutics Q3 net loss per share $0.29
Nov 6 (Reuters) - Protagonist Therapeutics Inc
Protagonist Therapeutics prices offering of 3.53 mln common shares at $17 per share
Oct 11 (Reuters) - Protagonist Therapeutics Inc
Protagonist Therapeutics announces proposed public offering of common stock
Oct 11 (Reuters) - Protagonist Therapeutics Inc
Lilly Ventures Fund I reports 12.9 percent stake in Protagonist Therapeutics Inc as of Aug. 16
Protagonist Therapeutics Inc
Ra Capital reports 6.8 pct passive stake in Protagonist Therapeutics
Protagonist Therapeutics Inc
Adage Capital Partners reports 9.69 pct passive stake in Protagonist Therapeutics - SEC filing
Adage Capital Partners LP:Adage Capital Partners LP reports 9.69 pct passive stake in Protagonist Therapeutics Inc as of August 11, 2016 - SEC filing. Full Article
Johnson & Johnson reports 15 pct passive stake in Protagonist Therapeutics - SEC filing
Johnson & Johnson:Johnson & Johnson reports 15.0 pct passive stake in Protagonist Therapeutics Inc as of Aug. 16. Full Article
Protagonist Therapeutics shares open at $12.00 in debut
: Protagonist Therapeutics Inc shares open at $12.00 in debut, flat from the IPO price of $12.00 per share Further company coverage: [PTGX.O] ((Bangalore.newsroom@thomsonreuters.com;)). Full Article
BRIEF-Protagonist Therapeutics Discontinues Phase 2B Propel Trial Of PTG-100
* PROTAGONIST THERAPEUTICS DISCONTINUES PHASE 2B PROPEL TRIAL OF PTG-100 FOR THE TREATMENT OF ULCERATIVE COLITIS FOLLOWING INTERIM ANALYSIS